GILD

GILEAD SCIENCES INC

Healthcare • USA

Apr 05 • 04:00PM ET
102.50
+2.16 (+2.15%)
Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, a ... read more

Full Time Employees 18,000
Phone 650 574 3000
Website https://www.gilead.com
CEO Mr. Daniel P. O'Day
IPO Date 1992-01-22
Sector Healthcare
Industry Drug Manufacturers - General
Address 333 Lakeside Drive, Foster City, CA 94404
Balance Sheet
Total Cash $7,926,000,000
Total Debt $24,952,000,000
Current Ratio 1.37
Quick Ratio 1.00
Profitability
Gross Margin 78.29%
Net Margin 20.76%
ROE 31.13%
ROA 10.57%
ROIC 16.29%
Balance Sheet
Total Cash $7,926,000,000
Total Debt $24,952,000,000
Current Ratio 1.37
Quick Ratio 1.00
Profitability
Gross Margin 78.29%
Net Margin 20.76%
ROE 31.13%
ROA 10.57%
ROIC 16.29%
Name GILEAD SCIENCES INC Sector Healthcare Currency USD Relative Volume 1.46 Market Cap 133563
Current Ratio 1.6 Dividend / Share 3.08 EPS 0.38 Revenue 28754000000 P/S 4.6
P/E 278.3 Beta 0.18 Income 480000000 Volume 12852383 Average Volume 8779615
Distance to 200DMA 20.3% 200 DMA 89.15 50 DMA 107.08 ROA 0.9 ROE 2.6
Distance to 50DMA 0.16% Return 1Y 56.9% Return YTD 16.93% Forward PE Qtly Growth YOY
Debt/Eq 2.06 P/B 6.9 Dividend Yield 3.3% Net Margin 1.67% Payout Ratio 810.5
Performance
52 Week Range 810.5%
Distance to 200DMA 1.5%
Day Change Percent $1.54
Performance Week $0.77
Performance Month $0.77
Performance Quarter 2024-09-13
Performance YTD $0.77
Performance Year $0.77

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $5,037,000,000
Total Debt $23,249,000,000
Current Ratio 1.26%
Quick Ratio 0.82%
Profitability
Gross Margin 78.29%
Net Margin 20.76%
ROE 31.13%
ROA 10.57%
ROIC 16.29%
Valuation
Price to Earnings 21.41
Price to Book 6.67
Price to Sales 4.44
Price to Free Cash Flow 12.97
Dividends
Payout Ratio 64.75%
Dividend Yield 3.02%
Dividend Amount $1.54
Last Dividend Pay Date 2024-09-13
Last Dividend Paid $0.77
Performance
52 Week Range 810.5%
Distance to 200DMA 1.5%
Day Change Percent $1.54
Performance Week $0.77
Performance Month $0.77
Performance Quarter 2024-09-13
Performance YTD $0.77
Performance Year $0.77
Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, a ... read more

Full Time Employees 18,000
Phone 650 574 3000
Website https://www.gilead.com
CEO Mr. Daniel P. O'Day
IPO Date 1992-01-22
Sector Healthcare
Address 333 Lakeside Drive, Foster City, CA 94404
Histogram - Daily

Balance Sheet
Total Cash $5,037,000,000
Total Debt $23,249,000,000
Current Ratio 1.26%
Quick Ratio 0.82%
Profitability
Gross Margin 0.7610%
Net Margin 0.0040%
ROE 0.01%
ROA 0.00%
Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, a ... read more

Full Time Employees 18,000
Phone 650 574 3000
Website https://www.gilead.com
CEO Mr. Daniel P. O'Day
IPO Date 1992-01-22
Sector Healthcare
Address 333 Lakeside Drive, Foster City, CA 94404
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

2 Dividend Stocks That are Holding Their Own in 2025
2 Dividend Stocks That are Holding Their Own in 2025

Perhaps it's not all too surprising to witness the S&P 500 run into turbulence after two of the best years for stock gains in recent memory.

2025-05-17 11:56:10 - 247wallst.com
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Tr

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society

2025-05-15 16:15:00 - businesswire.com
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

2025-05-15 10:01:04 - zacks.com
Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript
Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript

Gilead Sciences, Inc. (NASDAQ:GILD ) BofA Securities Health Care Conference May 13, 2025 2:20 PM ET Company Participants Johanna Mercier – Chief Commercial Officer Conference Call Participants Tim And

2025-05-13 19:32:37 - seekingalpha.com
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Dr. Scott Gottlieb: What to expect from President Trump's executive order to low

Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

2025-05-12 12:36:24 - youtube.com
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t

2025-05-12 12:30:03 - seekingalpha.com
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
2 High-Yield Dividend Stocks to Buy in May and Hold Forever

When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the most critical factor to consider is a company's underlying operations.

2025-05-10 08:45:00 - fool.com
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Pressure is still on the pharma sector, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

2025-05-08 19:23:04 - youtube.com
Gilead announces $11 billion in new investments in US
Gilead announces $11 billion in new investments in US

Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spending of $21 billion in domestic manufacturing and R&D through

2025-05-07 14:52:48 - reuters.com
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bule

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with ch

2025-05-07 02:30:00 - businesswire.com
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Rega

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the Europe

2025-05-07 02:15:00 - businesswire.com
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those

2025-05-02 07:02:25 - marketbeat.com
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure.

2025-04-30 10:10:48 - zacks.com
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

2025-04-30 10:06:02 - zacks.com
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Ca

2025-04-29 16:05:00 - businesswire.com